Boehringer Ingelheim bags a contract manufacturer, adding muscles for cancer vaccine, oncolytic virus programs
As Boehringer Ingelheim grows its pipeline of next-gen cancer therapies, it’s also beefing up the capacity to refine and make them.
The pharma giant is snapping up Labor Dr. Merk & Kollegen, a German contract development and manufacturing organization that’s carved out a niche in virology. For Boehringer, that expertise will come in handy for the oncolytic virus and cancer vaccine programs they got from acquiring ViraTherapeutics and AMAL Therapeutics.
“The trusting and highly effective collaboration between our scientists and the Labor Dr. Merk & Kollegen team has already contributed significantly to our progress in viral-based cancer therapies,” said Michel Pairet, a Boehringer board director overseeing the innovation unit.
Founded in 1971, Labor Dr. Merk & Kollegen is headquartered in Ochsenhausen, Germany, just a 20-minute drive from Boehringer’s Biberach R&D site. That development center was in turn part of a 2018 plan to double down on biologics.
Its staffers will continue to operate the site as a new unit of Boehringer, with an expansion planned for the future.
Beside cancer vaccines and oncolytic viruses, the German drugmaker has also signaled interest in T cell engagers, stromal modulators and myeloid cell modulators.